Pharmacoeconomic Guidelines: Iran
Country/Region: Iran
Submission Guidelines
Criteria for developing an economic evaluation file - 2017 to 2019
PDF in Farsi
PDF in Farsi
Submission Guidelines Source:
Information current as of Thursday, April 12, 2018
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | Submission Guidelines |
| Title and year of the document | Criteria for developing an economic evaluation file - 2017 to 2019 |
| Affiliation of authors | Dr. Cheraghali: Head of economic committee. Dr.Nikfar: Head of IDL committee. Dr. Dinarvand: previous Head of IFDA |
| Purpose of the document | Drug costs and resource constraints |
| Standard reporting format included | Two parts: Economic evaluation, budget impact |
| Disclosure | It should be declared |
| Target audience of funding/ author's interests | Without any conflict of interest with company |
| Perspective | Society, Payer |
| Indication | Indication approved by the Clinical Committee |
| Target population | Age, Sex, Geographic Distribution of Disease in the Country |
| Subgroup analysis | If there is evidence of better results in subgroups, analysis in subgroup should be done. |
| Choice of comparator | Comparator approved by the Clinical Committee |
| Time horizon | Based on Nature of the disease and treatment method and results |
| Assumptions required | According to feasibility of study and availability of data |
| Preferred analytical technique | Cost utility analysis (CUA), Cost Effectiveness analysis (CEA), Cost Minimization analysis (CMA) |
| Costs to be included | Direct Costs, Indirect Costs, Intangible Costs |
| Source of costs | Weighted average of the private and public sector |
| Modeling | Markov model, Treeage, Monte carlo |
| Systematic review of evidences | RCT, Meta analysis |
| Preference for effectiveness over efficacy | Prefered outcome measure |
| Preferred outcome measure | Life Year or QALY |
| Preferred method to derive utility | To complete generic form of quality of life questions |
| Equity issues stated | Not yet |
| Discounting costs | Yes |
| Discounting outcomes | Yes |
| Sensitivity analysis-parameters and range | Deterministic |
| Sensitivity analysis-methods | One way, Tornado |
| Presenting results | Provide results based on ICER |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Yes |
| Financial impact analysis | Yes |
| Mandatory or recommended or voluntary | Mandatory |
Acknowledgement: